Genelux (GNLX) Amortization - Deferred Charges (2023)

Genelux (GNLX) recorded quarterly Amortization - Deferred Charges of $108000.0 in Q1 2023.

Genelux (GNLX) Amortization - Deferred Charges (2023) Analysis & Trends

Genelux's Amortization - Deferred Charges history runs 1 years deep, the most recent figure standing at $108000.0 for Q1 2023.

In Q1 2023, Amortization - Deferred Charges changed N/A year-over-year to $108000.0; the TTM figure through Dec 2023 stood at $108000.0 (changed N/A YoY), while the FY2023 annual figure was $108000.0, up 77.05% from the prior year.
Amortization - Deferred Charges was $108000.0 for Q1 2023 at Genelux.
In the past five years, Amortization - Deferred Charges ranged from a high of $108000.0 in Q1 2023 to a low of $108000.0 in Q1 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Amortization - Deferred Charges (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Genelux	129.36 Mn	129.36 Mn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2023	108,000.00
Mar 31, 2023	108,000.00